# ğŸ“… Daily Report - 2026-02-14

> ä»Šæ—¥ç­›é€‰å‡º **61** æ¡å†…å®¹ï¼Œæ¥è‡ª **2** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
 KRASé©±åŠ¨çš„è‚¿ç˜¤å¾®ç¯å¢ƒå‡†å¤‡æœºåˆ¶ï¼Œæ¶‰åŠTNFÎ±ï¼Œä¸ºèƒ°è…ºç™Œå‘ç”Ÿå‰é“ºè®¾â€œæ¸©åºŠâ€ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- æ¢ç´¢KRASé©±åŠ¨çš„è‚¿ç˜¤å¾®ç¯å¢ƒå‡†å¤‡æœºåˆ¶ï¼ˆèƒ°è…ºç™Œï¼‰ã€‚
- é˜æ˜STAT5B SH2ç»“æ„åŸŸçªå˜å¯¹è‚è„èƒ†å›ºé†‡å’Œè„‚è´¨ä»£è°¢çš„å½±å“ã€‚
- ç ”ç©¶CDK7æŠ‘åˆ¶å‰‚åœ¨è‚¿ç˜¤æ²»ç–—ä¸­çš„ä½œç”¨åŠå…¶åˆ†å­æœºåˆ¶ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- æ•´åˆå•ç»†èƒè½¬å½•ç»„å­¦ä¸ç£·é…¸åŒ–è›‹ç™½è´¨ç»„å­¦ï¼Œè§£æEGFRè°ƒæ§çš®å±‚ç¥ç»èƒ¶è´¨å‘ç”Ÿç½‘ç»œã€‚
- ç©ºé—´è½¬å½•ç»„å­¦æŠ€æœ¯åº”ç”¨äºåˆ›ä¼¤æ€§è„‘æŸä¼¤ç ”ç©¶ï¼Œæ­ç¤º4-æ°¨åŸºå¡å•¶çš„æ²»ç–—æ½œåŠ›ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
ç§‘å­¦å®¶å‘ç°æ–°å‹è›‹ç™½è´¨èƒ½é€†è½¬è¡°è€è„‘ç»†èƒåŠŸèƒ½ï¼Œä¸ºç¥ç»å†ç”Ÿå¸¦æ¥æ–°å¸Œæœ›ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
-  è¯†åˆ«å¹¶éªŒè¯è°ƒæ§ç¥ç»å¹²ç»†èƒå†ç”Ÿèƒ½åŠ›çš„è›‹ç™½è´¨ã€‚
-  è§£æå°è¡Œæ˜Ÿæ’å‡»ç‰©ä¸­æ°¨åŸºé…¸çš„å…¨æ–°å½¢æˆæœºåˆ¶ã€‚
-  å¼€å‘æ–°å‹å•ç»†èƒRNAæµ‹åºåˆ†æå·¥å…·ï¼Œç»˜åˆ¶ä»£è°¢ç‰©ä»‹å¯¼çš„ç»†èƒé€šè®¯å›¾è°±ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
-  åˆ©ç”¨RNAæµ‹åºä¸ä»£è°¢æ¨¡å‹ç›¸ç»“åˆï¼Œé¦–æ¬¡å®ç°å¯¹ä»£è°¢ç‰©é©±åŠ¨çš„ç»†èƒé—´é€šè®¯è¿›è¡Œå¯è§†åŒ–åˆ†æã€‚
-  å‘ç°DMTF1è›‹ç™½åœ¨æ¢å¤è¡°è€ç¥ç»å¹²ç»†èƒå†ç”Ÿèƒ½åŠ›ä¸­çš„å…³é”®ä½œç”¨ã€‚

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (58æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **GSE312209 è‡´ç™Œ KRAS é©±åŠ¨çš„åˆ†æ³Œç»„æ¶‰åŠ TNFÎ±ï¼Œä¿ƒè¿›èƒ°è…ºç™Œå‘ç”Ÿå‰çš„å¾®ç¯å¢ƒå‡†å¤‡ [å…±åŸ¹å…» scRNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€regex:onco(logy|logist|gene|genic)ã€scRNAã€KRAS
- ğŸ“ **æè¿°**ï¼šContributors : Chantal Allgoewer ; Markus Breunig ; Alexander KlegerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBackground: Pancreatic ductal adenocarcinomas (PDACs) are highly lethal and aggressive with oncogenic KRAS being the main oncogenic driver of the disease. PDACs have been extensively profiled at advanced stages, and in advanced disease the tumor microenvironment is a major determinant that critically shapes patient outcomes. Since the molecular events occurring prior to invasive growth remain poorly understood, we aimed to investigate changes in the precancerous epithelium and its surrounding niche.Methods: We acquired time-resolved, single-cell transcriptomic (scRNAseq), and accessible-chromatin data from human pluripotent stem cell-derived pancreatic duct-like organoids (PDLO) inducibly expressing KRASG12D and from various niche cells. Results: Analysis of the pure epithelium already revealed key signatures of matrix remodeling and inflammation-related signaling upon few days of KRASG12D expression. Machine learning captured KRASG12D-dependent transcriptomic classifiers with high prediction accuracy and niche preparatory relevance. Various co-culture approaches followed by scRNAseq and functional validation, including T-cell microfluidics, demonstrated that the KRASG12D-induced PDLO-secretome activates pancreatic stellate cells (PaSCs) and protects precancerous organoids from T cell infiltration. Additional, in silico approaches reconstructed a virtual pancreatic (pre)cancerous space to profile cell-cell interactions between PDLOs and niche cells. TNFÎ± emerged as a top-ranked ligand and was functionally validated to mediate T-cell shielding and PaSC activation. Cyst fluid from 80 prospectively sampled Intraductal Papillary Mucinous Neoplasm (IPMNs) â€“well-known cystic PDAC precursor lesionsâ€“ showed a stepwise TNFÎ± rise across LGD (low-grade), HGD (high-grade), and IC (invasive cancer).Conclusion: Our study reveals that oncogenic KRAS orchestrates niche-preparatory programs that precede PDAC formation and highlight a T cell exclusion program governed by epithelial-derived TNFÎ±.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312209)

**2.** â­ **GSE284392 è‡´ç™Œ KRAS é©±åŠ¨çš„åˆ†æ³Œç»„æ¶‰åŠ TNFÎ±ï¼Œä¿ƒè¿›èƒ°è…ºç™Œå‘ç”Ÿå‰çš„å¾®ç¯å¢ƒå‡†å¤‡ [æ—¶é—´åºåˆ— scRNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€regex:onco(logy|logist|gene|genic)ã€scRNAã€KRAS
- ğŸ“ **æè¿°**ï¼šContributors : Chantal Allgoewer ; Markus Breunig ; Alexander KlegerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBackground: Pancreatic ductal adenocarcinomas (PDACs) are highly lethal and aggressive with oncogenic KRAS being the main oncogenic driver of the disease. PDACs have been extensively profiled at advanced stages, and in advanced disease the tumor microenvironment is a major determinant that critically shapes patient outcomes. Since the molecular events occurring prior to invasive growth remain poorly understood, we aimed to investigate changes in the precancerous epithelium and its surrounding niche.Methods: We acquired time-resolved, single-cell transcriptomic (scRNAseq), and accessible-chromatin data from human pluripotent stem cell-derived pancreatic duct-like organoids (PDLO) inducibly expressing KRASG12D and from various niche cells. Results: Analysis of the pure epithelium already revealed key signatures of matrix remodeling and inflammation-related signaling upon few days of KRASG12D expression. Machine learning captured KRASG12D-dependent transcriptomic classifiers with high prediction accuracy and niche preparatory relevance. Various co-culture approaches followed by scRNAseq and functional validation, including T-cell microfluidics, demonstrated that the KRASG12D-induced PDLO-secretome activates pancreatic stellate cells (PaSCs) and protects precancerous organoids from T cell infiltration. Additional, in silico approaches reconstructed a virtual pancreatic (pre)cancerous space to profile cell-cell interactions between PDLOs and niche cells. TNFÎ± emerged as a top-ranked ligand and was functionally validated to mediate T-cell shielding and PaSC activation. Cyst fluid from 80 prospectively sampled Intraductal Papillary Mucinous Neoplasm (IPMNs) â€“well-known cystic PDAC precursor lesionsâ€“ showed a stepwise TNFÎ± rise across LGD (low-grade), HGD (high-grade), and IC (invasive cancer).Conclusion: Our study reveals that oncogenic KRAS orchestrates niche-preparatory programs that precede PDAC formation and highlight a T cell exclusion program governed by epithelial-derived TNFÎ±.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284392)

**3.** â­ **GSE284390 è‡´ç™Œ KRAS é©±åŠ¨çš„åˆ†æ³Œç»„æ¶‰åŠ TNFÎ±ï¼Œä¿ƒè¿›èƒ°è…ºç™Œå‘ç”Ÿå‰çš„å¾®ç¯å¢ƒå‡†å¤‡ [ATAC-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€regex:onco(logy|logist|gene|genic)ã€ATAC-seqã€KRAS
- ğŸ“ **æè¿°**ï¼šContributors : Chantal Allgoewer ; Markus Breunig ; Alexander KlegerSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensBackground: Pancreatic ductal adenocarcinomas (PDACs) are highly lethal and aggressive with oncogenic KRAS being the main oncogenic driver of the disease. PDACs have been extensively profiled at advanced stages, and in advanced disease the tumor microenvironment is a major determinant that critically shapes patient outcomes. Since the molecular events occurring prior to invasive growth remain poorly understood, we aimed to investigate changes in the precancerous epithelium and its surrounding niche.Methods: We acquired time-resolved, single-cell transcriptomic (scRNAseq), and accessible-chromatin data from human pluripotent stem cell-derived pancreatic duct-like organoids (PDLO) inducibly expressing KRASG12D and from various niche cells. Results: Analysis of the pure epithelium already revealed key signatures of matrix remodeling and inflammation-related signaling upon few days of KRASG12D expression. Machine learning captured KRASG12D-dependent transcriptomic classifiers with high prediction accuracy and niche preparatory relevance. Various co-culture approaches followed by scRNAseq and functional validation, including T-cell microfluidics, demonstrated that the KRASG12D-induced PDLO-secretome activates pancreatic stellate cells (PaSCs) and protects precancerous organoids from T cell infiltration. Additional, in silico approaches reconstructed a virtual pancreatic (pre)cancerous space to profile cell-cell interactions between PDLOs and niche cells. TNFÎ± emerged as a top-ranked ligand and was functionally validated to mediate T-cell shielding and PaSC activation. Cyst fluid from 80 prospectively sampled Intraductal Papillary Mucinous Neoplasm (IPMNs) â€“well-known cystic PDAC precursor lesionsâ€“ showed a stepwise TNFÎ± rise across LGD (low-grade), HGD (high-grade), and IC (invasive cancer).Conclusion: Our study reveals that oncogenic KRAS orchestrates niche-preparatory programs that precede PDAC formation and highlight a T cell exclusion program governed by epithelial-derived TNFÎ±.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284390)

**4.** â­ **GSE304485ï¼šæ¥è‡ª13ç§TCGAç™Œç—‡ç±»å‹å’Œæ­£å¸¸ç»„ç»‡çš„æ‰¹é‡RNA-SeqåŸºå› è¡¨è¾¾è°±ï¼Œç”¨äºè‚¿ç˜¤åˆ†ç±»**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€TCGAã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributor : Sergii BabichevSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThis dataset includes bulk RNA-Seq gene expression profiles of 6310 samples from 13 cancer types and normal tissues, obtained from The Cancer Genome Atlas (TCGA) and processed using a standardized pipeline. The raw count matrix, initially containing 60,660 genes, was filtered to retain only valid ENTREZ gene identifiers matched via the org.Hs.eg.db annotation package. Genes with zero variance across samples were removed. Normalization was performed by transforming expression values into log2 Counts Per Million (CPM) using the edgeR::cpm() function with log transformation. To ensure all values were positive and suitable for downstream modeling, a global shift was applied by adding the absolute minimum value. Subsequently, Gene Ontology (GO) analysis was performed across all three categories (Biological Process, Molecular Function, Cellular Component) using the TopGO package. Significant genes were selected, followed by Benjaminiâ€“Hochberg p-value correction, and validated using both Fisherâ€™s and Kolmogorovâ€“Smirnov tests. The resulting expression matrix consists of 18,564 functionally relevant genes across 6310 samples and forms the basis for clustering, classification, and metric evaluation within hybrid modeling frameworks for cancer diagnostics.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304485)

**5.** â­ **GSE319409 åˆ©ç”¨ç©ºé—´è½¬å½•ç»„å­¦ç»˜åˆ¶åˆ›ä¼¤æ€§è„‘æŸä¼¤çš„ç»§å‘ååº”å›¾è°±æ˜¾ç¤ºï¼Œæ€¥æ€§ 4-æ°¨åŸºå¡å•¶æ²»ç–—å¯å‡è½»è½´çªå’Œåˆ†å­ç—…ç†å­¦**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šspatialã€spatial transcriptomicsã€transcriptomics
- ğŸ“ **æè¿°**ï¼šContributors : Genevieve M Sullivan ; Kryslaine L Radomski ; Shaoqiu He ; Matthew D Wilkerson ; Clifton L Dalgard ; Camille Alba ; Xiaomei Zi ; Martin L Doughty ; Regina C ArmstrongSeries Type : OtherOrganism : Mus musculusDamage to long myelinated axons of white matter tracts is a hallmark pathology resulting from traumatic brain injury (TBI) forces and secondary injury processes. 4-aminopyridine (4-AP) is an FDA-approved Kv1 potassium channel inhibitor designed to mitigate axon dysfunction. We examined repurposing 4-AP as an acute TBI treatment using clinically-oriented neuropathology of axon damage combined with unbiased genome-wide spatial transcriptomics for comprehensive analysis of secondary injury processes. Adult male and female mice received a non-penetrating impact TBI with 4-AP (i.p., b.i.d) on days 1-7 post-injury. Along corpus callosum (CC) axons, TBI disrupted node of Ranvier domains, exposing the putative 4-AP target of mislocalized Kv1 channels (p < 0.005). Clinically reasonable 4-AP dosing (0.5 mg/kg) reduced nodal Nav1.6 channel loss (p < 0.05) and Caspr heminode formation (p < 0.005) after injury. Quantification of Î²-amyloid precursor protein immunolabeling showed significantly reduced CC axon damage at 4-AP doses of 0.5 mg/kg and 5 mg/kg (each p < 0.005). 4-AP safety, based on potential seizure risk after TBI, was unaltered with vehicle or 0.5 mg/kg 4-AP, while the 5 mg/kg dose induced seizure behavior in sham and TBI groups (p < 0.0001). Spatial transcriptomics mapped molecular signatures to tissue pathology. TBI increased axonal injury response genes in the CC and in motor and somatosensory cortex sites of CC projection neurons. TBI induced disease-associated glial phenotypes that mapped predominantly within the CC. TBI increased pathway expression for immune and vascular functions, neuron and glial cell signaling, and cellular dyshomeostasis, while reducing expression in myelination-related pathways. Gene expression analysis of 4-AP treatment (0.5 mg/kg) indicated potassium channel target engagement and increased neuroaxonal activity, along with dampened secondary injury responses. Collectively, these findings reveal underlying molecular pathology of the secondary injury response and advance 4-AP translation to reduce axon damage and stimulate activity-dependent repair after acute TBI.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319409)

**6.** â­ **GSE294652 äººç±» CAR-T ç»†èƒæ ·æœ¬çš„å•ç»†èƒ RNA æµ‹åºæ•°æ®**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šT cellã€sequencingã€single-cell
- ğŸ“ **æè¿°**ï¼šContributors : Yuki Okuhiro ; Yasuhiro Kojima ; Hiroyoshi NishikawaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensRaw RNA sequencing data derived from human CAR-T cell samples are deposited in this repository. The datasets include bulk single-cell RNA-seq reads generated for research purposes.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294652)

**7.** **GSE310017 STAT5B SH2 ç»“æ„åŸŸä¸Šçš„ç–¾ç—…ç›¸å…³çªå˜è°ƒèŠ‚è‚è„ä¸­çš„èƒ†å›ºé†‡å’Œè„‚è´¨ä»£è°¢ [RNA-Seq è‚è„]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šmetabolismã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributor : Hye Kyung LeeSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusGrowth hormone (GH) signaling through STAT5B is a central regulator of hepatic metabolism, yet the functional consequences of disease-associated STAT5B variants remain poorly understood. Here, we generated mice carrying STAT5BY665F (gain-of-function) and STAT5BY665H (loss-of-function) alleles using CRISPR/Cas9-mediated base editing to dissect their impact on metabolic regulation. STAT5BY665F mutants developed hepatic lipid accumulation, hypercholesterolemia, and enhanced insulin sensitivity, whereas STAT5BY665H mice displayed reduced body weight and impaired insulin responsiveness. Transcriptomic analyses revealed that STAT5BY665F strongly activated lipid, cholesterol, and immune transcriptional programs, while STAT5BY665H failed to induce these pathways. ChIP-seq demonstrated extensive STAT5BY665F enhancer occupancy at metabolic and immune loci, contrasting with the minimal chromatin engagement of STAT5BY665H. Beyond the liver, STAT5BY665F broadly reprogrammed adipose tissue gene expression, activating lipid metabolism and immune regulatory networks, whereas STAT5BY665H exerted more restricted effects. Notably, transcriptional and chromatin remodeling by STAT5B variants displayed sex-dependent differences, with male livers showing more pronounced reprogramming than females. Together, these findings illustrate how alterations in STAT5B activity that alter enhancer activation led to altered metabolic function in liver and adipose tissue.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310017)

**8.** **GSE309955 STAT5B SH2 ç»“æ„åŸŸä¸Šçš„ç–¾ç—…ç›¸å…³çªå˜è°ƒèŠ‚è‚è„ä¸­çš„èƒ†å›ºé†‡å’Œè„‚è´¨ä»£è°¢ [RNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šmetabolismã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributor : Hye Kyung LeeSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusGrowth hormone (GH) signaling through STAT5B is a central regulator of hepatic metabolism, yet the functional consequences of disease-associated STAT5B variants remain poorly understood. Here, we generated mice carrying STAT5BY665F (gain-of-function) and STAT5BY665H (loss-of-function) alleles using CRISPR/Cas9-mediated base editing to dissect their impact on metabolic regulation. STAT5BY665F mutants developed hepatic lipid accumulation, hypercholesterolemia, and enhanced insulin sensitivity, whereas STAT5BY665H mice displayed reduced body weight and impaired insulin responsiveness. Transcriptomic analyses revealed that STAT5BY665F strongly activated lipid, cholesterol, and immune transcriptional programs, while STAT5BY665H failed to induce these pathways. ChIP-seq demonstrated extensive STAT5BY665F enhancer occupancy at metabolic and immune loci, contrasting with the minimal chromatin engagement of STAT5BY665H. Beyond the liver, STAT5BY665F broadly reprogrammed adipose tissue gene expression, activating lipid metabolism and immune regulatory networks, whereas STAT5BY665H exerted more restricted effects. Notably, transcriptional and chromatin remodeling by STAT5B variants displayed sex-dependent differences, with male livers showing more pronounced reprogramming than females. Together, these findings illustrate how alterations in STAT5B activity that alter enhancer activation led to altered metabolic function in liver and adipose tissue.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309955)

**9.** **GSE309954 STAT5B SH2 ç»“æ„åŸŸä¸Šçš„ç–¾ç—…ç›¸å…³çªå˜è°ƒèŠ‚è‚è„ä¸­çš„èƒ†å›ºé†‡å’Œè„‚è´¨ä»£è°¢ [ChIP-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šmetabolismã€ChIP-seq
- ğŸ“ **æè¿°**ï¼šContributor : Hye Kyung LeeSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusGrowth hormone (GH) signaling through STAT5B is a central regulator of hepatic metabolism, yet the functional consequences of disease-associated STAT5B variants remain poorly understood. Here, we generated mice carrying STAT5BY665F (gain-of-function) and STAT5BY665H (loss-of-function) alleles using CRISPR/Cas9-mediated base editing to dissect their impact on metabolic regulation. STAT5BY665F mutants developed hepatic lipid accumulation, hypercholesterolemia, and enhanced insulin sensitivity, whereas STAT5BY665H mice displayed reduced body weight and impaired insulin responsiveness. Transcriptomic analyses revealed that STAT5BY665F strongly activated lipid, cholesterol, and immune transcriptional programs, while STAT5BY665H failed to induce these pathways. ChIP-seq demonstrated extensive STAT5BY665F enhancer occupancy at metabolic and immune loci, contrasting with the minimal chromatin engagement of STAT5BY665H. Beyond the liver, STAT5BY665F broadly reprogrammed adipose tissue gene expression, activating lipid metabolism and immune regulatory networks, whereas STAT5BY665H exerted more restricted effects. Notably, transcriptional and chromatin remodeling by STAT5B variants displayed sex-dependent differences, with male livers showing more pronounced reprogramming than females. Together, these findings illustrate how alterations in STAT5B activity that alter enhancer activation led to altered metabolic function in liver and adipose tissue.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309954)

**10.** **GSE301206 ç»„è›‹ç™½ä¹³é…¸åŒ–ä»‹å¯¼çš„è¡€ç®¡å¹³æ»‘è‚Œç»†èƒä»£è°¢é‡å¡‘é€šè¿‡ä¿ƒè¿›ä¹³é…¸ç§¯ç´¯åŠ å‰§ä¸»åŠ¨è„‰ç˜¤å’Œä¸»åŠ¨è„‰å¤¹å±‚ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šmetabolicã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Liwei Liu ; Aijun Sun ; Junbo GeSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensThe phenotypic switch of vascular smooth muscle cells (VSMCs) is a crucial pathogenesis in aortic aneurysm and dissection (AAD), metabolic remodeling from oxidative phosphorylation (OXPHOS) to glycolysis involved in the process. Histone lactylation expression was analyzed in aorta of aortic aneurysm (AA) patients and AAD mice, as well as the AngII(angiotensin II)-treated VSMCs. CUT&Tag was used to explore the downstream target gene for H4K16 lactylation (H4K16la) between AngII-induced VSMCs and Control. The finding was to explore the impact of histone lactylation (H4K16la) on the progress of AAD.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301206)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 48 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-æ•°æ®å‰æ²¿)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰

**1.** **MEBOCOSTâ€”â€”åˆ©ç”¨å•ç»†èƒRNAæµ‹åºç»˜åˆ¶ä»£è°¢ç‰©ä»‹å¯¼çš„ç»†èƒé—´é€šè®¯å›¾è°±**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRNA-seqã€single-cell
- ğŸ“ **æè¿°**ï¼šUsing RNA sequencing and metabolic modeling, researchers developed MEBOCOST to map metabolite driven cell communication, revealing new insights into adipose tissue biology...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/mebocost-mapping-metabolite-mediated-intercellular-communications-using-single-cell-rna-seq-2/)

**2.** **ç§‘å­¦å®¶å‘ç°ä¸€ç§èƒ½å¤Ÿä½¿è¡°è€è„‘ç»†èƒæ¢å¤æ´»åŠ›çš„è›‹ç™½è´¨**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šaging
- ğŸ“ **æè¿°**ï¼šA newly identified protein may hold the key to rejuvenating aging brain cells. Researchers found that boosting DMTF1 can restore the ability of neural stem cells to regenerate, even when age-related damage has set in. Without it, these cells struggle to renew and support memory and learning. The findings raise hopes for treatments that could slow or even reverse aspects of brain aging.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/02/260212025620.htm)

**3.** **å°è¡Œæ˜Ÿè´åŠªæ­ç¤ºäº†ç”Ÿå‘½åŒ–å­¦çš„æ–°é€”å¾„**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼špathway
- ğŸ“ **æè¿°**ï¼šDust from asteroid Bennu is revealing a surprising origin story for lifeâ€™s building blocks. New research suggests some amino acids formed in frozen ice exposed to radiation, not warm liquid water as scientists long believed. Isotopic clues show Bennuâ€™s chemistry differs sharply from well-studied meteorites, pointing to multiple pathways for creating lifeâ€™s ingredients.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/02/260212023024.htm)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| RNA-seq | 10 |
| cancer | 6 |
| spatial | 6 |
| single-cell | 5 |
| metabolism | 5 |
| ATAC-seq | 5 |
| sequencing | 5 |
| ChIP-seq | 4 |
| tumor | 3 |
| pathway | 3 |
| regex:onco(logy|logist|gene|genic) | 3 |
| scRNA | 3 |
| KRAS | 3 |
| metabolic | 3 |
| transcriptome | 3 |
| antibody | 3 |
| T cell | 3 |
| immunity | 2 |
| histone | 2 |
| kinase | 2 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (48æ¡)</summary>

<div class="details-content" markdown="1">

- [GSE292907 é€‰æ‹©æ€§ CDK7 æŠ‘åˆ¶é€šè¿‡é˜»æ–­ RNA èšåˆé…¶ II èµ·å§‹å¤åˆç‰©å‘å»¶ä¼¸çš„è½¬å˜ï¼Œä½¿è‚¿ç˜¤å¯¹æ‹“æ‰‘å¼‚æ„é…¶ I æŠ‘åˆ¶å‰‚-æŠ—ä½“è¯ç‰©å¶è”ç‰©æ•æ„Ÿ [ChIP-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292907)
- [GSE292860 é€‰æ‹©æ€§ CDK7 æŠ‘åˆ¶é€šè¿‡é˜»æ–­ RNA èšåˆé…¶ II èµ·å§‹å¤åˆç‰©å‘å»¶ä¼¸çš„è½¬å˜ï¼Œä½¿è‚¿ç˜¤å¯¹æ‹“æ‰‘å¼‚æ„é…¶ I æŠ‘åˆ¶å‰‚-æŠ—ä½“è¯ç‰©å¶è”ç‰©æ•æ„Ÿ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292860)
- [GSE312193 DDX53 é©±åŠ¨äººç±» TCam-2 ç»†èƒçš„è½¬å½•ç»„å˜åŒ–ï¼ˆRNA-seq æ•°æ®ï¼‰](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312193)
- [GSE309309 ä¸­æœŸå†·å†»ä¿å­˜å’Œè½¬å½•ç»„åˆ†æä½œä¸ºè¯†åˆ«ç”¨äºæ€¥æ€§é«“ç³»ç™½è¡€ç—…å…ç–«æ²»ç–—çš„åŠŸèƒ½æ€§NKç»†èƒæ‰©å¢æœ€ä½³ä¾›ä½“çš„ç­–ç•¥](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309309)
- [GSE300791 å¢å¼ºå­åŠ¨åŠ›å­¦å’Œç©ºé—´ç»„ç»‡é©±åŠ¨äººç±»è„Šé«“ä¸­è§£å‰–å­¦ä¸Šå—é™çš„ç»†èƒçŠ¶æ€ [scRNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300791)
- [GSE300782 å¢å¼ºå­åŠ¨åŠ›å­¦å’Œç©ºé—´ç»„ç»‡é©±åŠ¨äººç±»è„Šé«“ä¸­è§£å‰–å­¦é™åˆ¶çš„ç»†èƒçŠ¶æ€ [ATAC-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300782)
- [GSE282496 ç ”ç©¶å‘ç°ï¼Œæ–°ç”Ÿå„¿å¹¼ç¨š CD4+ T ç»†èƒè¡¨è¾¾ CD38ï¼Œè¿™å¡‘é€ äº†å®ƒä»¬ç‹¬ç‰¹çš„ä»£è°¢çŠ¶æ€å’Œé«˜è°ƒèŠ‚æ€§ T ç»†èƒæ½œèƒ½ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282496)
- [GSE319341ï¼šæ•´åˆå•ç»†èƒè½¬å½•ç»„å­¦å’Œç£·é…¸åŒ–è›‹ç™½è´¨ç»„å­¦ï¼Œè§£æè°ƒæ§çš®è´¨èƒ¶è´¨ç»†èƒç”Ÿæˆçš„EGFRä¾èµ–æ€§ç½‘ç»œ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319341)
- [GSE292266 åˆ©ç”¨ sci-L3-Strand-seq è¿›è¡Œå•ç»†èƒæ¨¡æ¿é“¾æµ‹åºçš„é«˜é€šé‡çº¿æ€§æ‰©å¢](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292266)
- [GSE318830 LncRNA NAS1 ç¼ºé™·é©±åŠ¨éå°ç»†èƒè‚ºç™Œçš„é¡ºé“‚è€è¯æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318830)
- [GSE300637 æ‰¹é‡ RNA-seq æ•°æ®é›†æ”¯æŒå¯¹èƒ¸è…ºç»†èƒå’Œ T ç»†èƒæ€¥æ€§æ·‹å·´ç»†èƒç™½è¡€ç—… (T-ALL) ä¸­ MYCâ€“USP10â€“SOX4 é€šè·¯çš„åˆ†æã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300637)
- [GSE289711 ç»„è›‹ç™½å˜ä½“ H2A.Z å¯¹ Epstein-Barr ç—…æ¯’æ½œä¼çš„è°ƒæ§ [ChIP-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289711)
- [GSE319375 è‚ºæ³¡å·¨å™¬ç»†èƒçš„è®­ç»ƒå…ç–«é€šè¿‡å¢å¼º KLF4-MERTK ä»‹å¯¼çš„èƒåä½œç”¨ä¿ƒè¿›æŸä¼¤æ¶ˆé€€ [2]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319375)
- [GSE319368 çš®å±‚ç¥–ç»†èƒçš„å¤šæ ·æ€§æŒ‡å¯¼ç¥ç»å…ƒå±‚å½¢æˆå’ŒåŒºåŸŸèƒ¶è´¨ç»†èƒæ¨¡å¼å½¢æˆ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319368)
- [GSE319345 èƒ†ç®¡ç»“æ‰åè‚å†…èƒ†ç®¡ä¸Šçš®ç»†èƒçš„å•ç»†èƒ RNA æµ‹åºã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319345)
- [GSE317656 Erastinè¯±å¯¼çš„é“æ­»äº¡å¢å¼ºè‡ªç„¶æ€ä¼¤ç»†èƒçš„æŠ—è‚¿ç˜¤æ´»æ€§ï¼Œå¹¶æœ‰æœ›ç”¨äºæ²»ç–—ç¥ç»æ¯ç»†èƒç˜¤](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317656)
- [GSE315862 é¶å‘éåŒæºæœ«ç«¯è¿æ¥é€”å¾„ä½¿ MDM2 æ‰©å¢çš„è„‚è‚ªè‚‰ç˜¤å¯¹é˜¿éœ‰ç´ è¯±å¯¼çš„è¡°è€å’Œ p53 ä»‹å¯¼çš„è¡°è€æ•æ„Ÿã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315862)
- [GSE310018 Disease-associated mutations on the STAT5B SH2 domain regulate cholesterol and lipid metabolism in liver](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310018)
- [GSE301003 é‡ç—‡é—´æ—¥ç–ŸåŸè™«ç–Ÿç–¾ä¸­ vir åŸºå› çš„æ¯”è¾ƒä¸´åºŠè½¬å½•ç»„](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301003)
- [GSE300144 å¯¹é—´æ—¥ç–ŸåŸè™«ä¸´åºŠåˆ†ç¦»æ ªï¼ˆåŒ…æ‹¬éå¤æ‚æ€§ç–¾ç—…å’Œå¤æ‚æ€§ç–¾ç—…ï¼‰ä¸­çš„æ­£ä¹‰å’Œå¤©ç„¶åä¹‰è½¬å½•æœ¬ (NAT) è¿›è¡Œå…¨è½¬å½•ç»„åˆ†æã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300144)
- [GSE292846 é€‰æ‹©æ€§ CDK7 æŠ‘åˆ¶é€šè¿‡é˜»æ–­ RNA èšåˆé…¶ II èµ·å§‹å¤åˆç‰©å‘å»¶ä¼¸çš„è½¬å˜ï¼Œä½¿è‚¿ç˜¤å¯¹æ‹“æ‰‘å¼‚æ„é…¶ I æŠ‘åˆ¶å‰‚-æŠ—ä½“è¯ç‰©å¶è”ç‰©æ•æ„Ÿ [fastGRO]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292846)
- [GSE281817 Dbf4ä¾èµ–æ€§æ¿€é…¶åœ¨æŸ“è‰²ä½“å¤åˆ¶èµ·ç‚¹å¾®è°ƒINO80åŠŸèƒ½](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281817)
- [GSE279121 æŸ“è‰²è´¨é‡å¡‘å› å­ Arp9 è°ƒèŠ‚é»„æ›²éœ‰çš„è€è¯æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279121)
- [GSE261739 äºŒæ¶è‹±æ˜¯ä¸€ç§å†…åˆ†æ³Œå¹²æ‰°ç‰©ï¼Œå­å®«å†…æš´éœ²ä¼šå¯¹ç”·æ€§ DNA ç”²åŸºåŒ–äº§ç”Ÿé•¿æœŸå½±å“ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE261739)
- [GSE318972 Î²ç»†èƒä¸­çªè§¦è›‹ç™½4çš„å¯Œé›†å¯é˜»æ­¢éè‚¥èƒ–ç³–å°¿ç—…ï¼ˆNODï¼‰å°é¼ å‘è‡ªèº«å…ç–«æ€§ç³–å°¿ç—…çš„è½¬åŒ–](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318972)
- [GSE318481 äº¤æ„Ÿç¥ç»-æˆçº¤ç»´ç»†èƒç›¸äº’ä½œç”¨é©±åŠ¨èƒ°è…ºç™Œä¸­çš„ç¥ç»æŸä¼¤ã€æˆçº¤ç»´ç»†èƒæ´»åŒ–å’ŒåŸºè´¨é‡å¡‘](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318481)
- [GSE312430 è¡°è€å…³èŠ‚æ»‘è†œå·¨å™¬ç»†èƒçš„æ€§åˆ«ç›¸å…³å˜åŒ–](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312430)
- [GSE306921 æ–°è¿›åŒ–çš„å†…æºæ€§é€†è½¬å½•ç—…æ¯’å¯åŠ¨åµå·¢å‚¨å¤‡ä»¥è¿›è¡Œæ¿€æ´» [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306921)
- [GSE306919 æ–°è¿›åŒ–çš„å†…æºæ€§é€†è½¬å½•ç—…æ¯’å¯åŠ¨åµå·¢å‚¨å¤‡ä»¥è¿›è¡Œæ¿€æ´» [ATAC-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306919)
- [GSE304792 SP1åœ¨ç‰›å’Œäººç±»èƒšèƒåŸºå› ç»„æ¿€æ´»åŠæ—©æœŸèƒšèƒå‘è‚²ä¸­çš„ç‰©ç§ç‰¹å¼‚æ€§ä½œç”¨](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304792)
- [GSE300809 å¢å¼ºå­åŠ¨åŠ›å­¦å’Œç©ºé—´ç»„ç»‡é©±åŠ¨äººç±»è„Šé«“ä¸­è§£å‰–å­¦é™åˆ¶çš„ç»†èƒçŠ¶æ€ [STABseq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300809)
- [GSE300798 å¢å¼ºå­åŠ¨åŠ›å­¦å’Œç©ºé—´ç»„ç»‡é©±åŠ¨äººç±»è„Šé«“ä¸­è§£å‰–å­¦ä¸Šå—é™çš„ç»†èƒçŠ¶æ€ [snRNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300798)
- [GSE300786 å¢å¼ºå­åŠ¨åŠ›å­¦å’Œç©ºé—´ç»„ç»‡é©±åŠ¨äººç±»è„Šé«“ä¸­è§£å‰–å­¦é™åˆ¶çš„ç»†èƒçŠ¶æ€ [snATAC-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300786)
- [GSE296577 ä¸´åºŠè¯•éªŒä¸­å•æ¬¡æº¶ç˜¤ç—…æ¯’æ²»ç–—åæŒç»­çš„Tç»†èƒæ´»åŒ–å’Œå¯¹èƒ¶è´¨æ¯ç»†èƒç˜¤çš„ç»†èƒæ¯’æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296577)
- [GSE293356 å½¢æ€åˆ›æ–°æ— éœ€åŸºå› å…±é€‰ï¼šæœè‡æ€§æ¢³çš„è¿›åŒ–æ˜¯é€šè¿‡å‘è‚²èŠ‚å¥å’Œèƒ½é‡ä»£è°¢çš„å˜åŒ–å®ç°çš„](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293356)
- [GSE285755 LMO1 åœ¨ç¥ç»æ¯ç»†èƒç˜¤ç»†èƒä¸­çš„è¡¨è¾¾é‡ç¼–ç¨‹è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒä»¥ä¿ƒè¿›è½¬ç§»ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285755)
- [GSE317117 å¯¹æ„ŸæŸ“åµŒåˆ EV-A71 æ¯’æ ªçš„ç»†èƒè¿›è¡Œ RNA æµ‹åºåˆ†æï¼Œå…¶ä¸­ 3C è›‹ç™½é…¶åŒºåŸŸä¸å…¶ä»– EV-A71 æ¯’æ ªè¿›è¡Œäº†äº¤æ¢ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317117)
- [GSE312969 ä»¥å•ç»†èƒåˆ†è¾¨ç‡ç»˜åˆ¶ç»µç¾Šå‚ä½“é’æ˜¥æœŸç›¸å…³è°ƒæ§å›¾è°±](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312969)
- [GSE295191 RNAæµ‹åºæ•°æ®é›†æ¥è‡ªå°é¼ CD8é˜³æ€§Tç»†èƒ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295191)
- [GSE292265 è„‚è‚ªç»†èƒä¸­ RUNX1 æˆ– RUNX2 çš„åŸºå› ç¼ºå¤±å¢å¼ºäº†ç±³è‰²è„‚è‚ªçš„å½¢æˆ [ChIP-Seq; CUT&Tag]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292265)
- [GSE292124 è„‚è‚ªç»†èƒä¸­ RUNX1 æˆ– RUNX2 çš„åŸºå› ç¼ºå¤±å¢å¼ºäº†ç±³è‰²è„‚è‚ªçš„å½¢æˆ [ATAC-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292124)
- [GSE318881 RNA-Seqå®šé‡åˆ†ææ…¢æ€§ç²’ç»†èƒç™½è¡€ç—…æ‚£è€…è¡€æµ†å¤–æ³Œä½“å¯¹æ…¢æ€§ç²’ç»†èƒç™½è¡€ç—…ç»†èƒè½¬å½•ç»„çš„è°ƒæ§ä½œç”¨](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318881)
- [GSE318537 é€šè¿‡ç³»ç»Ÿé¶å‘å’ŒæŠ‘åˆ¶é‰´å®šéª¨çŸ¿ç‰©è´¨å¯†åº¦ GWAS ä½ç‚¹çš„ç›®æ ‡åŸºå› å’Œè°ƒæ§ç½‘ç»œ [hFOB ATAC-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318537)
- [GSE315711 ä»å¤å‘æ€§æ‰æ¡ƒä½“ç‚å’Œ IgA è‚¾ç—…æ‚£è€…çš„è…­æ‰æ¡ƒä½“ä¸­åˆ†ç¦»çš„æ»¤æ³¡é—´ Tfh ç»†èƒçš„æ‰¹é‡ RNA æµ‹åºã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315711)
- [GSE314708 å°èƒ¶è´¨ç»†èƒ TFEB æ¿€æ´»é€šè¿‡å¢å¼ºè‡ªå™¬-æº¶é…¶ä½“åŠŸèƒ½å‡è½»é˜¿å°”èŒ¨æµ·é»˜ç—…ç—…ç†](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314708)
- [GSE309901 è‚Œé†‡å…­ç£·é…¸æ¿€é…¶ (IP6K) æ°´å¹³é™ä½ä¼šæŸå®³å…‹æ°é”¥è™«åœ¨äººç±»å¿ƒè‚Œç»†èƒå†…çš„ç”Ÿå‘½å‘¨æœŸè½¬å˜å’Œç»†èƒå†…å‘è‚²](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309901)
- [GSE307982 PTMA ä¿æŠ¤çº¿ç²’ä½“å®Œæ•´æ€§ä»¥ç»´æŒ CD8+ T ç»†èƒçš„ä»£è°¢åŠŸèƒ½å’ŒæŠ—è‚¿ç˜¤æŒä¹…æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307982)
- [GSE288513 Scapç¨³å®šPKM2ä»¥ä¿ƒè¿›ç³–é…µè§£å¹¶å¢å¼ºå·¨å™¬ç»†èƒçš„æŠ—çœŸèŒå…ç–«åŠ›](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288513)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-13 21:56*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*